ClearPoint Neuro (NASDAQ:CLPT) vs. Venus Concept (NASDAQ:VERO) Critical Comparison

Venus Concept (NASDAQ:VERO – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Venus Concept and ClearPoint Neuro, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Venus Concept 1 0 0 0 1.00
ClearPoint Neuro 1 0 2 0 2.33

ClearPoint Neuro has a consensus price target of $24.33, indicating a potential upside of 252.15%. Given ClearPoint Neuro’s stronger consensus rating and higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Venus Concept.

Volatility and Risk

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.

Profitability

This table compares Venus Concept and ClearPoint Neuro’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Venus Concept -92.76% -1,904.25% -85.22%
ClearPoint Neuro -79.43% -170.24% -37.00%

Valuation & Earnings

This table compares Venus Concept and ClearPoint Neuro”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Venus Concept $58.88 million 0.01 -$47.00 million ($48.84) -0.01
ClearPoint Neuro $45.49 million 4.87 -$25.54 million ($1.21) -5.71

ClearPoint Neuro has lower revenue, but higher earnings than Venus Concept. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 28.0% of Venus Concept shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ClearPoint Neuro beats Venus Concept on 10 of the 14 factors compared between the two stocks.

About Venus Concept

(Get Free Report)

Venus Concept is a medical technology company that develops and markets devices for aesthetic and hair-restoration procedures. Its systems are designed for use by medical and aesthetic professionals in clinics and other treatment settings. The company’s product portfolio includes technologies for skin resurfacing, hair removal, body contouring and skin tightening, as well as hair-transplant systems such as NeoGraft and ARTAS. Its devices use approaches including radiofrequency, laser and light-based energy.

About ClearPoint Neuro

(Get Free Report)

ClearPoint Neuro develops technologies used to plan, guide and monitor minimally invasive procedures in the brain and spine. Its product portfolio includes MRI-guided navigation systems and instruments for neurosurgery, including tools for laser ablation and for delivering therapeutics to targeted areas of the central nervous system. The company also works with biotechnology and pharmaceutical partners on the delivery of cell and gene therapies and other biologics to the brain. Its platforms are designed to support accurate placement and monitoring during procedures and in clinical research.

Receive News & Ratings for Venus Concept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venus Concept and related companies with MarketBeat.com's FREE daily email newsletter.